Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ATRC · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortAtriCure, Inc. is loss-making, generates cash and holds more cash than debt, with revenue growing (+14.9% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1.8% | 11/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -2.1% | 11/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -2.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -1.3% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.96× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.13× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -1.61× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.44 | 60/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 9.0% | 56/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 7.0% | 85/100 |
| Operating margin volatility | 13.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 17.4% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 274 | 330 | 399 | 465 | 535 |
| Cost of revenue | 68 | 84 | 99 | 118 | 134 |
| Gross profit | 206 | 246 | 300 | 348 | 401 |
| Research & development | 49 | 57 | 74 | 96 | 99 |
| Selling, general & admin | 205 | 231 | 253 | 291 | 311 |
| Operating income | 55 | (43) | (27) | (40) | (9.4) |
| Interest expense | 4.9 | 5 | 6.9 | 6.4 | 5.9 |
| Pre-tax income | 50 | (46) | (30) | (44) | (10) |
| Income tax | 0.2 | 0.3 | 0.6 | 1 | 1.3 |
| Net income | 50 | (46) | (30) | (45) | (11) |
| Diluted EPS | $1.09 | −$1.02 | −$0.66 | −$0.95 | −$0.24 |
| Diluted shares (millions) | 46 | 46 | 46 | 47 | 48 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
3.44 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 27, 2026